Co-Diagnostics, Inc. — Form 8-K
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Co-Diagnostics implemented a 1-for-25 reverse stock split of its common stock, effective November 24, 2026, reducing outstanding shares from 13,044,465 to approximately 521,779 shares. The reverse split was approved by shareholders on November 13, 2026, and is intended to maintain Nasdaq compliance with the $1.00 minimum bid price requirement and preserve authorized shares for future equity financing. Fractional shares were rounded up to whole shares; no other changes to capitalization or par value occurred.
Why this rating
Reverse split is routine capital structure action common for small-cap Nasdaq stocks; does not change business economics, revenue, or asset value—only mechanical share count adjustment.
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.